Schroder Investment Management Group Acquires 260,940 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Schroder Investment Management Group increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 87.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 558,798 shares of the biotechnology company’s stock after purchasing an additional 260,940 shares during the period. Schroder Investment Management Group owned approximately 0.20% of Exelixis worth $18,831,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Tri Ri Asset Management Corp bought a new position in Exelixis in the third quarter valued at approximately $4,396,000. Blue Trust Inc. lifted its position in Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 8,208 shares in the last quarter. Range Financial Group LLC acquired a new position in Exelixis in the 4th quarter worth $994,000. FMR LLC increased its holdings in Exelixis by 6.1% during the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock worth $63,891,000 after purchasing an additional 140,568 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after purchasing an additional 704,786 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Barclays upped their price objective on Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Truist Financial upped their price target on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Stephens reiterated an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. Stifel Nicolaus increased their target price on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Wednesday, February 12th. Finally, Wells Fargo & Company lowered shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price target on the stock. in a research note on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.59.

Insider Buying and Selling

In other Exelixis news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the transaction, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock worth $5,177,234. Company insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

Shares of EXEL stock opened at $37.04 on Thursday. The company has a market capitalization of $10.37 billion, a price-to-earnings ratio of 20.93, a PEG ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02. The company has a 50-day simple moving average of $35.80 and a 200 day simple moving average of $33.48.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Sell-side analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.